Discordance between immunofixation and free light chain assays in multiple myeloma: a retrospective analysis and evaluation of the heavy/light chain assay for disease monitoring
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00130-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 06.03.2026. Verfasst von Oytip Nathalang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Accurate detection and monitoring of monoclonal proteins in multiple myeloma (MM) are critical for diagnosis and treatment guidance. Conventional assays such as serum protein electrophoresis (SPEP), immunofixation electrophoresis (SIFE), and serum-free light chain (SFLC) testing can yield discordant or inconclusive results, particularly in patients with low M-protein levels.
Objectives
To evaluate the concordance and discordance between SIFE and SFLC assays in MM and to assess the clinical utility of the heavy/light chain (HLC) assay as a complementary quantitative tool.
Methods
We retrospectively analyzed 1,310 MM patient samples. The concordance and discordance between SIFE and SFLC were assessed, and the analytical performance of HLC measurements was evaluated relative to conventional assays.
Results
The overall discordance rate between SIFE and SFLC was 26.9%, with SIFE–/SFLC + most frequent in light chain MM and SIFE + /SFLC– observed in patients who achieved a very good partial response (VGPR). HLC strongly correlated with total immunoglobulins (combined immunoglobulin G [IgG]/immunoglobulin A [IgA], R 2 = 0.99) and SPEP ( R 2 = 0.94). HLC ratios demonstrated excellent concordance with SIFE ( κ = 0.83, 95% confidence interval [CI] 0.72–0.93) but poor agreement with SFLC ratios ( κ = 0.01, 95% CI − 0.18–0.20). Using the HLC response model, 15 patients classified as having VGPR by the International Myeloma Working Group (IMWG) criteria were reclassified as having a partial response due to a dHLC reduction of < 90%.
Conclusions
This large retrospective study provides a comprehensive evaluation of SIFE and SFLC discordance in MM, offering real-world evidence of their complementary diagnostic and monitoring roles. These findings support the integration of HLC testing into existing response assessment strategies to enhance the accuracy of treatment evaluation and the interpretation of discordant results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Program in Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand.
- Division of Hematology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
- Division of Hematology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand. dollapak.a@gmail.com.
- Department of Pathology, Phramongkutklao College of Medicine, Ratchathewi District, 316 Ratchawithi Road, Bangkok, 10400, Thailand. dollapak.a@gmail.com.
Zitieren
APA
Nathalang, O., Onthong, Y., Laoruangroj, C., & Apipongrat, D. (2026). Discordance between immunofixation and free light chain assays in multiple myeloma: a retrospective analysis and evaluation of the heavy/light chain assay for disease monitoring. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00130-9
Vancouver
Nathalang O, Onthong Y, Laoruangroj C, Apipongrat D. Discordance between immunofixation and free light chain assays in multiple myeloma: a retrospective analysis and evaluation of the heavy/light chain assay for disease monitoring. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00130-9
BibTeX
@article{Nathalang2026,
author = {Nathalang, Oytip and Onthong, Yupapin and Laoruangroj, Chonlada and Apipongrat, Dollapak},
title = {Discordance between immunofixation and free light chain assays in multiple myeloma: a retrospective analysis and evaluation of the heavy/light chain assay for disease monitoring},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00130-9}
}
EUVIMED